Sleep architecture, delta waves and the two peptides people file under insomnia

A night's rest is scored as architecture before it is a peptide. Two characterised sequences keep getting filed under insomnia, and they are not a licensed hypnotic. DSIP is a nine-residue peptide isolated from the blood leaving a sleeping rabbit brain. Epithalon is a four-residue pineal tetrapeptide whose papers sit on nocturnal melatonin amplitude and on TERT in fibroblasts. They share a filing, not a receptor, and they share neither a mechanism nor a clinic indication. This is the map of those two paper trails: sleep architecture as a scored EEG night, delta waves as a frequency, the pineal as a darkness factory, and the gap between an isolation story and a hypnotic. Mapping isn't treating. A characterised cake is a reagent. Cognitive behavioural therapy for insomnia, a dark room, and the medicines a sleep clinic already writes still live where they lived when this page was closed.

In short. Two research peptides sit behind searches for insomnia. They share a filing, not a receptor. We'll map both paper trails.

Let's write the letters out before anyone is allowed a caption. DSIP is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, WAGGDASGE on a certificate, about 849 daltons, CAS 62568-57-4, nine residues pulled by Schoenenberger and Monnier from rabbit cerebral venous blood during electrically induced delta-wave sleep and published in the Proceedings of the National Academy of Sciences in 1977. Epithalon is Ala-Glu-Asp-Gly, AEDG, about 390 daltons, a synthetic tetrapeptide from Vladimir Khavinson's pineal-peptide programme in St Petersburg, the defined stand-in for the extract epithalamin. Melatonin, the hormone people mash both of them into, is N-acetyl-5-methoxytryptamine, an indoleamine written by pineal AANAT after the suprachiasmatic nucleus has certified night. Three carbon skeletons. Three assays. It's easy to hear them as one night in a vial. The chromatogram is the better witness. What follows is architecture, isolation chemistry, a mixed DSIP literature with no clean GPCR, pineal melatonin amplitude, TERT in a dish, and the endocrine night that still does more work than either sequence.

In short. DSIP is nine letters from a 1977 isolation. Epithalon is four letters from a pineal school. Melatonin is a different molecule again.

Insomnia is a complaint. Sleep is an endocrine programme. Slow-wave pulses of growth hormone fire when the cortex is writing high-amplitude delta. Cortisol should trough around midnight and rise toward dawn so hepatic glucose is ready for waking. Melatonin is a darkness certificate, not a drowsy feeling in a bottle: nanomolar indoleamine in blood and CSF after AANAT has been induced by nocturnal norepinephrine. Miss the architecture and you miss a chunk of that programme, which is why Spiegel, Leproult and Van Cauter could wreck next-day glucose tolerance in healthy young men by taking the night apart, and why a peptide isolated during delta sleep is still not a substitute for the night in which delta actually occurred. Dark rooms and a stable clock still do more work than either vial, and we'll say so in the same voice that names the sequences. If you typed can't sleep, those are the two sequences this catalogue actually holds. Hold the complaint, the programme, and the two paper trails at once, or the chemistry starts doing marketing's job.

In short. Sleep is a timed hormone programme: growth hormone at slow waves, cortisol down at midnight, melatonin as a darkness signal. A complaint is not that programme.

A night of mammalian sleep isn't one state. It is a repeating conversation between non-rapid-eye-movement sleep and REM, scored from the electroencephalogram, the electro-oculogram and muscle tone, in cycles that in a healthy adult last about ninety minutes. Non-REM is staged N1, N2 and N3. N1 is the doorway: alpha drops, theta appears, a person who denies having slept can still have been in it. N2 is the bulk of a typical night, marked by sleep spindles — brief 11 to 16 hertz bursts from thalamic reticular neurons — and by K complexes, large biphasic waves that are still, among other jobs, a gate against arousal. N3 is slow-wave sleep, delta sleep in the older tongue: high-amplitude waves below 4 hertz, the stage whose name DSIP borrowed. REM is a different physiology entirely, with a desynchronised EEG, rapid saccades, and skeletal atonia except for the diaphragm and the extra-ocular muscles. Four or five such cycles in a seven-hour night is the textbook drawing. The drawing is a census. It isn't a personality, and it isn't a peptide.

In short. Adult sleep runs in roughly ninety-minute cycles of light sleep, deep delta sleep and REM. Those stages are scored from brain waves, eye movements and muscle tone.

Rechtschaffen and Kales published the scoring manual in 1968, a paper-and-pencil consensus that trained a generation of technicians to call stages from paper EEG. The American Academy of Sleep Medicine revised the rules in 2007: N1, N2, N3 instead of S1 through S4, with the old S3 and S4 collapsed into a single slow-wave stage because the distinction was less reliable than the field had pretended. Delta, in the AASM rule, is 0.5 to 2 hertz activity of at least 75 microvolts peak-to-peak, occupying a sufficient fraction of the epoch. Slow-wave activity as a spectral measure, usually 0.5 to 4 hertz power, is the continuous cousin of that binary call and the number you actually want if the claim is that a ligand moved architecture. Polysomnography is the machine: scalp EEG, EOG, submental EMG, airflow, thoraco-abdominal effort, oximetry, often pretibial EMG for periodic limb movements. A sleep diary isn't that machine. A wearable that guesses stages from a wrist isn't that machine either, however convenient the plot. If a peptide paper reports sleep without saying which of those instruments wrote the score, it has reported a mood.

In short. Sleep stages are called from a tracing, by named rules. A diary or a wrist gadget is not the same measurement as a scored night in a lab.

N1 and N2 aren't filler, which is the first mistake a caption makes when it has fallen in love with delta. Spindles are a thalamocortical rhythm with a documented relationship to memory consolidation and to the gating of sensory arousals; they slow with age, they change in schizophrenia and in some epilepsies, and they are a legitimate endpoint. K complexes are evoked and spontaneous, a cortical down-state in miniature, and they too are scored because they mark N2 rather than because they are picturesque. Wake after sleep onset, sleep-onset latency, and sleep efficiency — time asleep over time in bed — are the insomnia numbers a trial actually moves, and they are mostly N1/N2 and arousal arithmetic, not a delta-power headline. A ligand that increased delta at the expense of sleep continuity would have traded one architecture for another. A ligand that shortened latency without touching N3 would still have moved a clinical insomnia number. Architecture is a table of stages, latencies and arousals. Deep sleep as a synonym for a good night skips that table.

In short. Light sleep with spindles and K complexes is most of the night and carries its own jobs. Insomnia trials often move latency and awakenings, not a delta headline.

N3 is the stage the isolation paper pointed at, so it deserves a slower paragraph. Slow-wave sleep is concentrated in the first two cycles of a night in a young adult, then cedes the later cycles to REM. The waves are large because large patches of cortex are flipping, roughly together, between a depolarised up-state and a hyperpolarised down-state, paced by thalamocortical loops and by the cortical need to discharge the prior day's synaptic load. Tononi and Cirelli's synaptic-homeostasis hypothesis is one reading of that discharge; it isn't the only reading, and we won't pick a favourite. What isn't in dispute is the electrophysiology: high-amplitude delta, a high arousal threshold, a growth-hormone-permissive window, and a homeostatic debt that builds with prior wake. Adenosine is the local metabolite most often named as that debt's coin. Caffeine is an adenosine-receptor antagonist, which is why an espresso at 16:00 is an architecture experiment whether or not anyone scored it. Delta is a frequency and a stage. It isn't a brand, and it isn't a nonapeptide.

In short. Deep sleep is slow, large brain waves early in the night. It pays back a debt that builds while you are awake. That frequency is not a product name.

A delta wave is an oscillation, classically 0.5 to 4 hertz, of high amplitude relative to the waking EEG, generated when thalamocortical relay cells fall into burst mode and cortex follows. Steriade's intracellular work in the 1990s is still the physiology you'd cite if you're going to talk about how the wave is made: a clock in the thalamus, a cortical down-state, a loop. Scalp EEG sees a smeared version of that loop, larger over frontal electrodes in adult N3, which is why a single central channel is a poor summary of slow-wave activity. Spectral power in the delta band can rise without a scorer calling more N3, and N3 can be scored without the power having moved much, depending on thresholds and on how much of the epoch the waves occupy. Those two measurements are related. They aren't identical. A peptide literature that says delta sleep went up without showing a hypnogram and a power spectrum hasn't yet said which measurement moved. Frequency first. Stage second. Both, if the claim is architecture.

In short. Delta is a slow brain-wave frequency made by thalamus and cortex talking. Stage N3 is a scoring call. They overlap. They are not the same number.

Homeostatic sleep pressure is the process that makes N3 greedy after sleep loss. Process S, in Borbély's two-process model, builds during wake and discharges during sleep, most steeply in the first cycles; Process C is the circadian gate, the SCN's permission for sleep and wake to occur at the right clock time. Delta power is the usual marker of S. A nap in the afternoon discharges some of it and can steal from the subsequent night's N3. A night of restriction leaves a remainder that the next night tries to pay, which is why recovery sleep is delta-rich and why a single delayed bedtime isn't a free lunch. Adenosine, prostaglandin D2, cytokines in illness, and a set of local cortical use-dependent changes all sit under that pressure. The model is older than DSIP's English fame and more predictive than a nonapeptide caption. If a ligand moved delta power, the adult question is whether it moved Process S, Process C, an arousal threshold, or a scoring artefact. Those are four experiments. The isolation paper named a stage. It didn't close which process the sequence sits on.

In short. Sleep pressure builds while you are awake and is paid down, especially as slow waves, when you sleep. A clock decides when that payment is allowed.

REM is the other half of the ninety-minute sentence, and treating it as a curiosity is how an architecture essay becomes a delta brochure. Atonia is the spinal fact: most skeletal motoneurons are actively inhibited, which is why a healthy sleeper doesn't act the dream. The EEG looks oddly wake-like, mixed-frequency, low-amplitude, with sawtooth waves and hippocampal theta in the animals that show it cleanly. Ponto-geniculo-occipital waves, in the cat literature that built the field, mark the brainstem generator. Acetylcholine from laterodorsal and pedunculopontine tegmental neurons is the classical REM-on chemistry; the ventrolateral periaqueductal grey and adjacent deep mesencephalic reticular neurons are REM-off; orexin/hypocretin from the lateral hypothalamus stabilises the switch, which is why narcolepsy, an orexin-cell loss, fragments the boundary. Licensed dual orexin-receptor antagonists — daridorexant, suvorexant, lemborexant — occupy that switch on purpose. They are hypnotics with a named GPCR pair. DSIP isn't in that sentence. A night that lost REM would still have architecture. It would have the wrong architecture.

In short. REM is a separate brain state with floppy muscles, darting eyes and a wake-like tracing. Orexin helps keep the switch stable. That is a different chemistry from DSIP.

Four to six cycles a night is the usual adult census, each about ninety minutes, with the N3 fraction falling and the REM fraction rising as the night proceeds. The first cycle may run shorter. The last REM period may run longer and is the one an alarm clock is most likely to interrupt. Infants cycle faster, more REM, a different architecture that isn't this essay. Ageing, in the other direction, thins N3, fragments continuity, advances the circadian phase in many people, and leaves a hypnogram that looks moth-eaten even when total time in bed hasn't fallen. That thinned N3 is one reason nocturnal growth-hormone pulses flatten with age, a sentence the GH-axis essay on this desk already owns. Architecture is therefore a lifespan object as well as a nightly object. A peptide isolated during delta sleep in a rabbit is being asked, by a search bar, to sit down at that lifespan table. Isolation during a state isn't occupancy of the generator of the state. The hypnogram is still the measurement that would decide.

In short. Early cycles are richer in deep sleep; later cycles are richer in REM. Ageing thins the deep part. Finding a peptide during deep sleep does not mean it runs the generator.

The largest growth-hormone pulses of a healthy adult day coincide with slow-wave sleep. Takahashi, then Van Cauter, then Veldhuis's deconvolution work: discrete bursts, most of the daily mass in those bursts, the first nocturnal pulse the biggest in young men. GHRH from the arcuate is permissive; somatostatin is the brake; the slow-wave window is when the brake is least in the way. Miss N3 and you miss a chunk of the daily GH integral. That's why night-time sampling exists, why a daytime secretagogue challenge is a different probe from a nocturnal endogenous pulse, and why the GH-axis essay on this desk keeps sending readers back to a hypnogram. Ageing flattens the pulse as it thins N3. Abdominal adiposity flattens it further. A GHRH analogue and a ghrelin-receptor pentapeptide can still occupy their receptors on a somatotroph that hasn't slept; they don't rebuild the window. Sleep is the native protocol those receptors already expected. Filing a delta-isolation nonapeptide next to that protocol is how a search talks. It isn't how a somatotroph is gated.

In short. The biggest growth-hormone bursts of the day ride deep sleep. Lose the slow waves and you lose a chunk of that signal. A peptide does not replace the window.

Cortisol should be a cliff, not a plateau. The ACTH rhythm, driven from the SCN via CRH neurons in the paraventricular nucleus, puts the nadir around midnight and the peak thirty to sixty minutes after waking. Flatten that curve — shift work, late light, a stressing evening that keeps CRH up — and hepatic glucose output stays inappropriately on through the small hours. In people with diabetes that residual output plus the morning ACTH peak is the dawn phenomenon: glucose already climbing before breakfast. Sleep restriction, even for a single night, moves next-day insulin sensitivity on a clamp. Spiegel, Leproult and Van Cauter, Lancet 1999, six nights of four-hour sleep in healthy young men, a breakfast glucose load that looked like a milder type 2, a blunted first-phase insulin dump. Later work showed you don't need six nights. The bread hadn't changed. The controller had. Ghrelin drifts up, leptin down, appetite follows. None of this needs a personality theory of willpower, and none of it is a DSIP result. It is the invoice the night already writes.

In short. Cortisol should be low at midnight and high after waking. Cut the night short and next-day blood sugar handling gets worse. That is measured physiology.

Melatonin belongs in this endocrine paragraph as the darkness signal, not as the hypnotic people want it to be. N-acetyl-5-methoxytryptamine is written in pinealocytes when AANAT is induced and stabilised by nocturnal norepinephrine. It occupies MT1 and MT2, both Gi-coupled GPCRs, on the SCN itself, on the pituitary, and on peripheral clocks. Physiological nocturnal concentrations are nanomolar. A milligram oral bolus is a different chemistry, a different receptor occupancy, a different half-life, and in the United Kingdom a different legal object depending on the preparation: Circadin is a prolonged-release melatonin medicine with a marketing authorisation in a named indication; a food-supplement melatonin is a different shelf; a research tetrapeptide that sits on pineal amplitude is a third. Melatonin at physiological levels is a calendar and a darkness certificate. At pharmacological levels it is also a modest hypnotic in some protocols, particularly for circadian-phase problems. Confusing those doses, and then confusing both with AEDG or with WAGGDASGE, is how a night becomes a shopping list. Keep the indoleamine named. Keep the peptides named. Keep the doses honest.

In short. Melatonin is the pineal's darkness hormone. A tablet dose is not the night-time blood level, and neither is a research peptide with a pineal paper trail.

Glymphatic clearance is the other metabolic invoice of a night, and it belongs here so the word sleep can't be reduced to hormones. Nedergaard's group, and the work that followed, argued that the interstitial space of the brain expands during sleep, that cerebrospinal fluid flushes metabolites including amyloid-β, and that the flush is larger in sleep than in wake. The details are still being argued: how much is NREM-specific, how much is vascular pulsatility, how much survives in humans as measured by imaging rather than by rodent two-photon. The argument is real even while the percentages move. Sleep is a maintenance state for a metabolically expensive organ, which is why a vial that claimed to replace a night would have to replace more than a latency number. This catalogue doesn't sell a glymphatic ligand. DSIP wasn't isolated as one. Filing the nonapeptide under autophagy or under brain-cleaning is a string match with the word sleep. It isn't a flux assay. The neighbouring proteostasis essay has already had to unmix that filing. Architecture first. Disposal second, and only with a named cargo.

In short. Sleep also looks like a night-time rinse of brain fluid. That work is still being measured. It is not a job either of these peptides was shown to do.

Insomnia disorder, in ICSD-3 and in DSM-5, is a complaint of difficulty initiating sleep, difficulty maintaining it, or waking earlier than wanted, with daytime consequence, given the opportunity to sleep. Chronic when it has lasted three months and occurs at least three nights a week. The diagnosis is the complaint plus the consequence plus the opportunity; it isn't a delta-power threshold, and it isn't a peptide deficiency. Short sleep that a person doesn't complain about is a different object. A delayed sleep-wake phase that looks like insomnia on a workday and looks like a clock problem on holiday is a circadian disorder, not the same letter. Paradoxical insomnia, a mismatch between the complaint and the polysomnogram, exists and is a reason a hypnogram still earns its keep. The clinic object is therefore several objects. Filing all of them under DSIP is how a search talks. An experiment that enrols insomnia without saying which of those sentences it means hasn't started from the clinic object. It has started from a word.

In short. Insomnia is a lasting problem getting to sleep or staying asleep, with a daytime cost, despite the chance to sleep. It is a complaint, not a missing peptide.

Cognitive behavioural therapy for insomnia is first-line in NICE-adjacent practice for a reason that has nothing to do with peptides. Stimulus control, sleep restriction as a therapeutic use of Process S, cognitive work on the clock-watching and the catastrophic forecast, a wind-down that is actually a wind-down: those are the tools, and they move sleep efficiency and the complaint in trials a hypnotic then has to beat. Licensed hypnotics in the United Kingdom sit in a different legal class from a research cake. Zopiclone and zolpidem occupy a benzodiazepine-sensitive site on GABA-A receptors and shorten latency; they also change architecture, often thinning N3 and REM, and they carry next-day impairment, dependence risk, and a deprescribing conversation. Prolonged-release melatonin has a marketing authorisation in a named older-adult indication. Daridorexant occupies OX1R and OX2R. None of those ligands is WAGGDASGE. None of them is AEDG. Naming them is how we keep the research solids from being mistaken for a formulary. A lyophilised nonapeptide doesn't inherit a hypnotic's indication by having been found during sleep.

In short. Talking therapy for insomnia is first-line. Licensed sleeping tablets occupy named receptors and have named risks. These research sequences are not that class of medicine.

Obstructive sleep apnoea is the other clinic object the search bar keeps shoving into the same bag. Repeated collapse of the pharyngeal airway, desaturation, an arousal that restores tone, a night of fragmented architecture that can look like insomnia to the person and looks like an apnoea-hypopnoea index to the scorer. Continuous positive airway pressure, a mandibular device, weight, surgery in selected anatomy: those are the tools. A peptide doesn't stent an airway. Restless legs and periodic limb movements are a third drawer, iron and dopamine in the conversation, a different hypnogram. Narcolepsy, already named above as orexin-cell loss, is a fourth. Circadian rhythm sleep-wake disorders are a fifth, and they are the ones that actually sit nearer the pineal half of this essay because the clock is the lesion. Unbundling is the job. Apnoea, restless legs, narcolepsy, a delayed phase, and chronic insomnia can all present as I can't sleep. Only one of those presentations is even adjacent to a pineal-amplitude literature, and none of them is a DSIP indication. The clinic still has to sort the drawer.

In short. Stopped breathing at night, restless legs, narcolepsy and a shifted body clock can all feel like insomnia. They are different problems. Neither peptide is a treatment for them.

Guido Schoenenberger and Marcel Monnier sampled the blood leaving a sleeping brain and found a nine-residue peptide. The 1977 PNAS paper is the document: characterization of a delta-electroencephalogram(-sleep)-inducing peptide, isolated from cerebral venous blood of rabbits in which electrical stimulation of thalamic intralaminar nuclei had produced a delta-wave EEG. They named it for the finding. The finding was a sequence in an effluent during a state. Subsequent work synthesised the nonapeptide, put it into other animals, and asked whether the named object still moved a hypnogram. Sometimes it did, in some species, at some doses, on some scoring rules. Sometimes it didn't. That mixed literature is the adult DSIP file, and it is thinner and less tidy than the name. Isolation during delta sleep is a provenance. Provenance is interesting. Provenance isn't a mechanism, not a receptor, and not a reason to caption a vial as a night's rest. This listing is that named nonapeptide, freeze-dried, HPLC-characterised. It is the sequence from the isolation story.

In short. In 1977 a nine-letter peptide was found in blood leaving a rabbit brain during deep sleep. They named it after that finding. A finding is not a sleeping tablet.

The isolation itself deserves a methods sentence, because isolation papers are easy to mythologise. Cerebral venous blood isn't a peripheral plasma sample. Concentrations in the effluent of a stimulated thalamus are a local conversation; they aren't a circulating hormone until someone has shown a peripheral rise that tracks the state. Electrical stimulation of intralaminar thalamus is a classical way to write delta onto a rabbit EEG; it is also a way to write a great many other peptides, metabolites and injury signals into the same venous sample. Chromatography, then sequencing, then synthesis of the putative nine-mer, then a bioassay in which the synthetic chain is asked to reproduce the EEG effect: that's the honest pipeline, and it is the pipeline Schoenenberger and Monnier ran. The synthetic chain is the object a catalogue can hold. The effluent isn't. Treating the 1977 isolation as a proof that the nonapeptide is the endogenous sleep hormone skips the difference between a factor found in a state and a factor that is necessary and sufficient for the state. Sleep has several such factors. Adenosine is one. DSIP has never earned that status.

In short. The peptide was taken from brain-vein blood during a stimulated deep-sleep state, then synthesised and tested. Being found in a state is not the same as causing the state.

WAGGDASGE is the chemistry. Tryptophan, alanine, glycine, glycine, aspartate, alanine, serine, glycine, glutamate. Nine residues, a free N-terminus in the classical sequence, a free C-terminus, molecular weight 848.8 if you take the monoisotopic-adjacent figure the certificates use, polar, charged at physiological pH on the aspartate and the glutamate, a tryptophan at the amino end that makes a 280-nanometre absorbance someone can actually use. There is no globular fold. There is no disulphide. There is no lipid anchor. Short peptides this size are ligands only if something in a membrane or a nucleus binds them with enough affinity and specificity to start a path, and they are lunch if the peptidases get there first. Extra-cerebral DSIP-like immunoreactivity was reported in later papers and then argued over, as radioimmunoassay of short peptides always is: antibodies see epitopes, not identities, and a nine-mer in plasma is a peptidase substrate. Characterisation on a modern HPLC-MS certificate is how you know the cake is the sequence. Immunoreactivity in a 1980s plasma isn't that certificate. The vial is the sequence.

In short. DSIP is nine amino acids, small, charged, with no folded shape. It only counts as a signal if something specific binds it before enzymes eat it.

The name tempts people to treat it as a hypnotic. Delta sleep-inducing peptide is a phrase that does a marketing department's work before a chromatogram has been run. The inducing in the original title was a bioassay claim in an animal whose thalamus had already been spoken to with an electrode. Later animal work sits on sleep architecture and on stress-axis markers, mixed, as that field is. Human papers exist and don't add up to a licensed hypnotic, a NICE recommendation, or a clean dose-response a sleep clinic would recognise. Zopiclone occupies a GABA-A site with a pharmacology a hospital already knows. DSIP doesn't. The honest sentence is the isolation sentence plus the mixed subsequent file. This vial is that sequence, freeze-dried. A dark bedroom is still a dark bedroom. CBT-I is still first-line. Treating the name as a mechanism is the original sin of this particular peptide, and it is the sin this page exists to refuse. A finding story is allowed to be interesting. It isn't allowed to be an indication.

In short. The name sounds like a sleeping tablet. The original test was in animals, and later work is mixed. The name describes a finding, not a licensed medicine.

After 1977 the nonapeptide went into cats, rats, rabbits, and eventually people, and the architecture results didn't settle. Some groups reported more delta, or a shorter latency, or a changed NREM/REM ratio. Some groups reported nothing that survived a vehicle and a proper score. Dose, route, species, whether the peptide was infused into a ventricle or given at the periphery, and whether the scorer was blind, all move the object. A nine-mer in a ventricle is a different experiment from a nine-mer in a vein, and neither is a person in a sleep laboratory with a pre-registered primary endpoint. Reviews from the 1980s and 1990s already had to say mixed. Reviews since haven't unmixed it. That's information. A literature that can't agree on whether the hypnogram moves isn't a literature you upgrade into a clinic caption. It is a literature you keep on a bench, with a chromatogram, a species, a route, and a scoring manual written down. Independent Western replications of a tidy delta-power effect remain thinner than the name. Hold the isolation. Hold the mix. Don't let the name referee the mix.

In short. Later animal and human tests of DSIP did not agree. Some nights looked different; some did not. A mixed file is not a clinic medicine.

No clean GPCR has been named, and that sentence is the mechanistic hole a visitor from another field will ask about first. Ipamorelin occupies GHSR. Retatrutide occupies GLP-1R, GIPR and GCGR. Zolpidem occupies a benzodiazepine-sensitive GABA-A site. Daridorexant occupies OX1R and OX2R. DSIP occupies, on the public record, nothing that a receptor nomenclature committee would stamp. Candidate bindings have been proposed over the decades — NMDA-adjacent effects, opioid-adjacent effects, a putative DSIP receptor that didn't survive as a cloned gene with a ligand blot — and none of them is a closed identification. Immunoreactive material isn't a receptor. A binding site on a gel isn't a gene symbol. Until someone shows a cloned receptor, a knockout that abolishes a named EEG effect, and a concentration at the site that matches the affinity, the nonapeptide is a sequence with a provenance and a mixed bioassay file. That's a lawful research object. It isn't a lock-and-key story. We won't invent the lock to make the filing tidier.

In short. Unlike many peptides with a named receptor, DSIP has none. Candidate bindings were proposed and not closed. The sequence is real. The lock is not.

The HPA-axis papers are the other DSIP drawer, and they are why a sleep-isolation story keeps turning up next to stress markers. Later work reported changes in ACTH, cortisol, or related peptides in animals given the nonapeptide, sometimes a quieting of a stress response, sometimes a shift that didn't replicate cleanly. The hypothalamic-pituitary-adrenal axis is itself a night-time object: CRH, ACTH, the midnight cortisol nadir already named. A ligand that sat on that axis could, in principle, move sleep because CRH is waking, or could move because the animal was less stressed and therefore slept, which is a different experiment from occupying a sleep-stage generator. Principle isn't a blot. The HPA file is mixed in the same way the hypnogram file is mixed, and it isn't a reason to caption the vial as anxiolytic, as anti-cortisol, or as a sleep medicine by another door. Named assays — a CRH challenge, a 24-hour cortisol curve, a vehicle, a species — would still be the programme. Filing DSIP under chill is doing the opposite of that programme.

In short. Some later DSIP papers sit on stress hormones rather than on sleep stages. That file is mixed too. Stress quieting is not the same experiment as writing delta.

Other claimed neighbourhoods — thermoregulation, blood pressure, a possible opioid-adjacent analgesia, NMDA modulation — show up in the older DSIP reviews and then fail to become a field. That pattern is familiar from other isolation-era peptides: a first paper, a burst of assays, a thinning as the receptor isn't cloned and the effects don't clean up. The honest way to read that burst is as a starting library, not as a closed canon, which is the same posture this journal already takes with Khavinson's TERT claims and with Zagreb's more extravagant BPC-157 extensions. Keep the isolation. Keep any assay that named a machine and a control. Let the rest wait for company. Thermoregulation is a real sleep-adjacent physiology — distal skin warming, a falling core temperature at sleep onset — and it has its own named pathways. DSIP hasn't earned a seat at that table with the kind of evidence a thermoregulation lab would need. Mentioning the burst is honesty about the file. Upgrading the burst is how a nine-mer becomes a legend.

In short. Older reviews also mention temperature, blood pressure and pain. Those leads did not become a clean field. Read them as unfinished, not as extra product claims.

How to read a mixed peptide literature is a skill, and DSIP is a good teacher because the name is so much tidier than the file. Count the species. Count the routes. Ask whether the scorer was blind and whether the primary endpoint was a hypnogram, a spectral band, a latency, or a hormone. Ask whether anyone cloned a receptor, and if they didn't, stop writing occupancy as if they had. Prefer a synthetic, HPLC-characterised nine-mer with a mass on the certificate over an immunoreactive DSIP that might be a related epitope. Prefer a vehicle-controlled, time-matched, light-controlled recording over a free-running animal in a noisy room. The 1977 isolation remains a beautiful methods story: venous effluent, a state, a sequence, a synthesis. Beauty isn't replication. The catalogue holds WAGGDASGE because the sequence is published and the assays are nameable. It doesn't hold a settled architecture effect, and this page won't write one into existence. Mixed is a result. Mixed is the result.

In short. Read DSIP by counting species, routes and whether the sleep tracing was scored blind. The 1977 isolation is real. A tidy human sleep effect is not.

Epithalon is four residues, AEDG, about 390 daltons, a synthetic tetrapeptide from Vladimir Khavinson's Institute of Bioregulation and Gerontology in St Petersburg. It began as a defined stand-in for epithalamin, a pineal extract. The headline claims that followed are that AEDG can switch TERT back on in ordinary fibroblasts, lengthen telomeres in those cultures, restore the night-time melatonin peak in old animals, and in some rodent studies move lifespan and tumour incidence. Those are measurable claims. They sit where three literatures already had names: Hayflick's finite-division census, the telomerase solution to the end-replication problem, and the pineal's darkness chemistry. Searchers file pineal and melatonin under sleep, which is why the tetrapeptide lands on an insomnia essay. The papers sit on nocturnal amplitude and TERT. Adjacent clock. Different ligand from DSIP. Ageing flattens the nocturnal melatonin peak even if the room is dark. Epithalon is a research question at that oscillator and at telomerase. It isn't sleep hygiene in four letters, and it isn't a second copy of the nonapeptide.

In short. Epithalon is four amino acids from a St Petersburg pineal programme. The papers sit on night-time melatonin in old animals and on telomerase in dishes, not on insomnia.

The reduction from extract to sequence is the scientifically honest move in the story, and it is the reason a catalogue holds AEDG rather than a pineal powder. An extract is a mixture: melatonin itself, other peptides, whatever else a pineal preparation carries. A tetrapeptide is a sequence you can synthesise, put a mass on a certificate, and ask whether the defined object still does what the extract did. Epithalamin is the extract. Epithalon, also spelled Epitalon in a large fraction of the English papers, is Ala-Glu-Asp-Gly. Anisimov's rodent lifespan and tumour-incidence tables sometimes used one reagent and sometimes the other; if you want to be about the tetrapeptide, you have to use the tetrapeptide and say so. Mixing them is how a reader cites an extract for a sequence result and then wonders why a replication failed. Four residues have no globular fold. Dose, termini, proteases, and how the peptide met the cell decide whether the experiment is still about AEDG. Characterisation isn't pedantry. It is identity.

In short. Epithalamin is a pineal mixture. Epithalon is the four-letter sequence made to stand in for it. A mixture and a sequence are not the same reagent.

Khavinson's literature reports restoration of nocturnal melatonin amplitude in aged animals as a recurring endpoint. That's a 24-hour assay with a dark control, a radioimmunoassay or LC-MS for the indoleamine, and an animal whose photoperiod you actually controlled. Ageing flattens the peak even when the room is dark: less AANAT competence, a noisier SCN, a pineal that has calcified in many human adults because pinealocytes live next to corpora arenacea and time isn't kind to that neighbourhood. A tetrapeptide that moved the flattened curve in an old rodent would be sitting on an axis — SCN, ganglion, AANAT, or the pinealocyte's competence to listen — and that's a 24-hour measurement, not a mood, not a latency, not a hypnogram. It is also not a sleep score in a person. Western labs have treated the pineal-amplitude papers as a starting library, not a closed canon, which is about right. An experiment that treats a dark-cycle control as optional hasn't yet earned the melatonin endpoint, with or without a peptide in the cage.

In short. Old animals lose the height of the night-time melatonin peak even in the dark. Epithalon papers ask whether that peak can be restored. That is a hormone curve, not a sleep score.

Human cells don't divide forever. Leonard Hayflick and Paul Moorhead showed that in 1961: diploid fibroblasts in culture divide, the population doubles some forty to sixty times, and then they stop, still alive, no longer mitotic. Hayflick didn't know the counter. Olovnikov and Watson named the shrinkage from the geometry of a lagging strand that polymerase can't finish. Blackburn, Greider and Szostak found the enzyme that can restock the end — telomerase, TERT plus the RNA template TERC — and took the 2009 Nobel. Most somatic cells silence TERT on purpose. That's the tumour-suppression bargain: a cell that can rebuild its telomeres without limit is a cell that has taken one of the brakes off neoplastic progression. Stem cells keep a trickle. The germline keeps more. Cancers usually reactivate TERT or use ALT, a recombination workaround. A tetrapeptide that claims to flip TERT back on in a fibroblast is interesting because of that bargain, not in spite of it. Interesting is the word the evidence currently earns. Sleep isn't the assay. The assay is TRAP, length, and karyotype.

In short. Cells in a dish divide a limited number of times because chromosome ends shorten. Telomerase can rebuild them and is kept off in most body cells on purpose.

Khavinson, Bondarev and colleagues reported, in the Bulletin of Experimental Biology and Medicine in 2003, that Epithalon induced telomerase activity and elongated telomeres in human somatic cells, specifically fetal fibroblast cultures. A 2004 follow-up reported extra doublings in those cells. Those two papers are the ones that still get cited whenever the molecule is discussed in English. They are cell-culture papers. TRAP, the telomeric repeat amplification protocol, asks whether telomerase is enzymatically active in a lysate; it is sensitive, which is a virtue and a hazard. Fetal fibroblasts are a particular object: they aren't senescent, they have more remaining telomere reserve than an adult dermal fibroblast, and they are closer to a developmental state in which TERT isn't as thoroughly locked off. A result in that dish is a result in that dish. It isn't a trial of telomere length in people, and it isn't a hypnogram. Independent Western replications remain thinner than the original corpus. Cite the papers as that literature. Don't inflate them into a human sleep outcome or a human telomere outcome.

In short. The 2003–2004 papers reported telomerase activity and longer chromosome ends in fetal cells in a dish. That is a culture result, not a human sleep trial.

Shelterin, named and dissected by Titia de Lange's laboratory, is six proteins that hide the chromosome end from the DNA-damage response and regulate how much telomerase, if any, is allowed to see that end. TRF1 and TRF2 bind double-stranded TTAGGG. POT1 binds the single-stranded G-overhang. TPP1 recruits telomerase when telomerase is allowed. TIN2 ties the complex. Rap1 sits on TRF2. The t-loop tucks the overhang back into the duplex so the end is a lariat, not a terminus. Without that hiding, every telomere would look like a double-strand break, ATM and ATR would fire constitutively, and the genome would fuse itself into chaos. A peptide literature that reports longer telomeres without mentioning these proteins has skipped the machine that actually holds the end. Length and capping are related; they aren't identical. Southern blots of terminal restriction fragments ask about length. A DNA-damage focus at a telomere asks about capping. Both belong in an experiment that claims AEDG moved the end. Sleep scoring isn't on that list, and putting it there is how a pineal tetrapeptide gets mistaken for a hypnotic.

In short. Six proteins cap chromosome ends so the cell does not treat them as broken DNA. A claim that telomeres grew still has to ask whether the cap held.

A TERT claim is a transcriptional claim, which is a different floor from a hypnogram. In most somatic cells the TERT promoter is in a repressed chromatin state. If AEDG does anything at that floor, something in packing, in the pre-initiation complex, in pausing, or in message stability moved — or an assay artefact looked like one of those. Khavinson's group has argued for a complementary-peptide interaction with promoter DNA. That isn't the mainstream model of how mammalian transcription factors work. Mainstream transcription factors are folded proteins with a DNA-binding surface that occupies a major groove as a structured object. Four residues can't fold into that handshake. Complementary peptide–DNA binding is possible in principle. Possible in principle isn't a solved occupancy at the TERT promoter. Independent Western molecular biologists would still call the mechanism unresolved. The useful response is a named assay: TERT mRNA, TRAP with heat and RNase controls, telomere length with the distribution shown, karyotype on the same cultures, promoter genotype so you aren't crediting a peptide for a C228T the line already had. A sleep latency isn't on that list.

In short. Saying Epithalon turns telomerase on is a claim about gene reading. The usual protein machines that read genes are not four amino acids. The mechanism is still open.

The pineal gland translates darkness into melatonin. Light hits intrinsically photosensitive retinal ganglion cells, melanopsin, peak sensitivity around 480 nanometres. The suprachiasmatic nucleus, about twenty thousand neurons above the optic chiasm, keeps a 24-hour transcription-translation loop: CLOCK and BMAL1 drive Period and Cryptochrome; PER and CRY proteins accumulate, repress CLOCK/BMAL1, degrade, and the cycle restarts. Takahashi, Tei, Reppert and Weaver spent the 1990s proving that this loop is the clock, not a metaphor for one. Only at night, after the SCN has certified darkness, does a multi-synapse path through the paraventricular hypothalamus and the intermediolateral column of the spinal cord end at the superior cervical ganglion, which then releases norepinephrine onto pinealocytes. Norepinephrine, via β1 and α1 adrenergic receptors, raises cAMP and calcium. AANAT, arylalkylamine N-acetyltransferase, is transcribed and stabilised. That enzyme acetylates serotonin to N-acetylserotonin. HIOMT, also called ASMT, then methylates that to melatonin. AANAT is the night-gated, rate-limiting step. Protein can rise tens-fold after dark and collapse in minutes if you turn a light on, because proteasomal degradation is the off-switch and cAMP is what holds it back.

In short. Light hits the eye, a small brain clock certifies night, and a long nerve path then tells the pineal to make melatonin from serotonin. The pineal is an output, not the clock itself.

David Klein's biochemistry is the reference for AANAT as the night enzyme. The anatomical joke of mammalian pineal melatonin is that the light doesn't hit the pineal. It hits the retina, the SCN computes night, and a nervous system writes a chemical. A pineal in a dish, disconnected, isn't a clock in the mammalian sense. Melatonin then leaves into blood and CSF and tells tissues that the organism is in the dark phase. At pharmacological concentrations it is also a radical scavenger. Physiological nocturnal nanomolar isn't the same chemistry as a milligram oral bolus, and neither is a tetrapeptide whose papers sit on the amplitude of the curve. Almost every tissue runs a version of the CLOCK/BMAL1 loop. The SCN is special because it is the only one that sees the outside world, via the retinohypothalamic tract, and then tells the others the time. Without that master, organs drift: a liver that thinks it is noon while the pancreas thinks it is midnight, and glucose handling is one of the first things to look drunk. The neighbouring circadian essay is the full map of that mismatch.

In short. In mammals the pineal does not see light itself. The eye and the master clock tell it when to run the night enzyme. Almost every organ has a clock; the master clock keeps them together.

Ageing flattens the nocturnal melatonin peak even when the room is dark. That sentence is the gerontology half of the pineal literature and the reason AEDG was asked the amplitude question in old animals rather than in a young one whose factory was already staffed. The SCN becomes noisier. AANAT induction is less decisive. The pineal accumulates corpora arenacea — brain sand — in many adults, a calcification that is ordinary and still a reminder that the gland isn't exempt from time. Shift work, late phones and polar winter are versions of a related insult: a transcriptional programme running on the wrong photoperiod, AANAT never fully firing, peripheral clocks drifting. IARC classifies night-shift work as a probable carcinogen in part because of that mismatch. Hepatic BMAL1 gates PEPCK and glucose-6-phosphatase. Pancreatic clocks gate insulin secretion. A flattened melatonin curve may be a cause of other ageing phenotypes or a marker of a clock that is already drifting; the field still argues. Either way, the measurement is a 24-hour indoleamine curve in controlled darkness, not a report that someone slept. Light is still the zeitgeber. Morning outdoor photons on melanopsin are still free.

In short. Getting older lowers the night melatonin peak even in a dark room. Shift work and late screens are a related mismatch. Morning light is still how the master clock is set.

A phone at 23:30 is a circadian input, not a physiology footnote. Melanopsin cares about blue-rich light around 480 nanometres; a 4000 K screen is an input to AANAT. Morning outdoor light is the correctly timed version of the same photon, the reset the SCN actually wants. Caffeine that still occupies adenosine receptors at midnight is a Process S experiment stacked on a Process C experiment. Eat a large glucose load when the liver is trying to go off-shift and you're running the Van Cauter experiment at home. None of these levers is a peptide. All of them move architecture and the endocrine night more reliably, in ordinary people, than either sequence in this essay has been shown to do. That isn't an insult to the papers. It is a sense of proportion an experiment is allowed to have. The sleep-and-glucose essay on this journal is ruder about phones at midnight, and it should be. Epithalon is a characterised tetrapeptide at the ageing-pineal intersection. DSIP is a characterised nonapeptide from a delta-isolation story. The photoperiod is still the control that costs nothing.

In short. A bright screen late at night is a light signal to the clock. Morning daylight, caffeine timing and meal timing still move a night more clearly than these peptides have.

Put the two ligands on the same bench and they still don't become a stack. DSIP is an isolation-from-sleep story: WAGGDASGE, rabbit cerebral venous blood, a mixed architecture and HPA file, no clean GPCR. Epithalon is a pineal-and-telomere story: AEDG, nocturnal melatonin amplitude in aged animals, TERT/TRAP in fetal fibroblasts, an open transcriptional mechanism. Melatonin is the indoleamine the pineal actually writes. A licensed hypnotic occupies GABA-A or an orexin receptor and lives on a formulary with a risk register. People bundle the first two because both papers mention night. Biochemistry doesn't bundle them. One is a nine-mer found during a state. One is a four-mer pointed at an oscillator and a reverse transcriptase. A damaged night in a person might, in principle, want architecture and a melatonin curve and a dark room. Principle isn't a protocol. Principle isn't a person. The catalogue lists both because a night-time reading list will meet both names. A button that puts both cakes in a bag, if a shop page offers one, is logistics for a bench. It isn't a combined-use instruction, and we won't write one.

In short. DSIP is a sleep-isolation nine-mer. Epithalon is a pineal four-mer on melatonin and telomerase. Melatonin and licensed sleeping tablets are different objects again. Not a combined plan.

Van Cauter's sleep-restriction work still explains more next-day glucose noise than either vial. That sentence is in the facts file for this slug and it stays here because it is the proportion a catalogue page owes. Spiegel 1999, later clamps, CGM-era replications after a single short night: insulin sensitivity falls, the breakfast curve looks drunk, ghrelin and leptin move. The neighbouring metabolism essay is the rude version. This peptide essay had to name the same work so that a reader who arrived from can't sleep wouldn't leave thinking a nonapeptide and a tetrapeptide were the first tools. Architecture, a dark window, morning light, caffeine timing, and, where the diagnosis is insomnia disorder, CBT-I, still do the everyday work. Where the diagnosis is apnoea, a mask does the work. Where the diagnosis is a delayed phase, timed light and, sometimes, timed melatonin as a medicine do the work. Research sequences sit on named assays inside that landscape. They don't own the landscape. Filing them first is how a journal becomes a stack.

In short. One short night already worsens next-day blood sugar in healthy adults. That finding still explains more everyday damage than either of these research peptides.

Three ligands people type when they type night, and a fourth they should type if they mean a hypnotic. Melatonin, N-acetyl-5-methoxytryptamine, pineal AANAT, MT1/MT2. DSIP, WAGGDASGE, isolation during delta, mixed architecture, no cloned receptor. Epithalon, AEDG, pineal amplitude and TERT. Zopiclone or daridorexant, GABA-A or orexin, a marketing authorisation. Four chromatograms. Four legal classes if you're in a country that has licensed the last and hasn't licensed the first three as sleep medicines, which the United Kingdom hasn't for DSIP or AEDG. Holding several peptides in one catalogue is easy. Holding them as the same kind of claim is how a reader ends up assaying the wrong one. The circadian essay next door is the darkness half: melanopsin, SCN, AANAT, shift work, phones at midnight, hepatic clocks gating glucose. The Epithalon essay is the telomere half, with the pineal as the other oscillator the tetrapeptide papers claimed. This piece is the insomnia filing: architecture first, then the two sequences people keep putting on that word, then the unmix.

In short. Night searches hit melatonin, DSIP, Epithalon and licensed sleeping tablets. Four different molecules. Four different jobs. This page is the unmix for the two research sequences.

Dark rooms and a stable clock still do more work than either vial. Process C wants a photoperiod: morning photons on melanopsin, darkness at the hour the pineal expects, a schedule that doesn't slide by two hours on Friday. Process S wants a wake long enough to build delta pressure and a consolidated night in which to discharge it, which is why sleep-restriction therapy, used carefully, can thicken N3 in people who have been spending ten hours in bed and sleeping six. Temperature, noise, a partner with apnoea, a dog, a phone: the unglamorous list a sleep clinic starts with because the list moves architecture. A characterised nonapeptide and a characterised tetrapeptide are how two literatures proposed to study a state and an oscillator. Those sentences can sit on the same page without one eating the other. An experiment that treats the dark-cycle control as optional hasn't yet earned either endpoint. A shop caption that treats the vials as the dark-cycle control hasn't yet earned the word architecture.

In short. A regular dark night and morning light still do more for sleep than these vials have been shown to do. The peptides are for named assays inside that physiology.

If the question is DSIP, the live assays are a hypnogram and a spectral band, in a named species, with a vehicle, a route, and a scorer who doesn't know which cage got the nine-mer. Sleep-onset latency, N3 minutes, delta power, REM fraction, wake after sleep onset: pick the primary before you thaw the cake. A 24-hour cortisol or ACTH curve is the HPA version of the same honesty, and it still needs a photoperiod you actually controlled. Receptor hunting, if anyone is still going to hunt, is a cloned gene, a knockout, a binding constant, and an EEG effect that dies when the gene dies. Immunoreactive DSIP in plasma is a 1980s measurement and a poor identity. A wearable stage plot is a convenience and a poor primary. A testimonial isn't on the list. The 10 mg listing is lyophilised WAGGDASGE, HPLC-characterised, for those assays and not for a bedtime story. If your experiment can't name the scoring manual, you aren't yet doing architecture. You're doing a caption.

In short. For DSIP, score a real sleep tracing with a dummy treatment as control, or measure a day's stress-hormone curve. A story about a good night is not an assay.

If the question is Epithalon, the live assays are a 24-hour melatonin curve in controlled darkness, TRAP with heat-inactivated and RNase-treated lysates, telomere length by Southern TRF or a T/S ratio with the distribution shown, and karyotype on the same cultures if extra doublings are the claim. Clock-gene panels, Per2 and Bmal1, ask whether a transcriptional loop moved. p53 and p16 status belong with a Hayflick claim because checkpoint loss is a different biography from TERT-on. Promoter genotype, C228T and C250T, so a peptide isn't credited for a mutation the line already had. Fetal fibroblasts aren't adult tissue and not a person. Anisimov's rodent lifespan and tumour tables are gerontology, strain- and husbandry-sensitive, and not a human outcome. Testimonials, before-and-after photographs, and forum threads aren't on that list. The 50 mg listing is lyophilised AEDG, HPLC-characterised, for those assays. Melatonin as a medicine, where it is a medicine, is a different legal object. The tetrapeptide doesn't inherit it.

In short. For Epithalon, measure a night-time melatonin curve, telomerase activity, chromosome-end length and a karyotype. A photograph is not that panel.

Compartmentation of the question is the variable most night-time peptide papers under-report. A ventricle and a vein are different experiments; so are a fetal fibroblast and a pinealocyte, and a pinealocyte and an SCN neuron. A rabbit hypnogram is a different object from an ICSD-3 insomnia complaint, and a melatonin curve is a different number from N3 minutes. If this sounds like a lot of work, that's because two ligands, four physiological objects, and a search bar that files them as one night is a lot of work. A kit on a homogenate is allowed as a scout. It isn't allowed as the only figure in an architecture title, and it isn't allowed as the only figure in a telomere title. Cell-type choice is a control, not a convenience. Aged animals if the claim is a flattened melatonin peak. Checkpoint-intact fibroblasts if the claim is TERT-on rather than crisis. A sleep-deprived control if the claim is Process S. A jet-lagged or short-photoperiod control if the claim is Process C. Pick the animal that has the job you are claiming. A search-bar complaint doesn't pick it for you.

In short. Say which tissue and which measurement you mean. Brain-fluid, blood, a dish of young cells and an old animal are different experiments. The search bar is not a protocol.

Let's retrace the architecture without the poster. Adult sleep runs in ninety-minute cycles of N1, N2, N3 and REM, scored from EEG, EOG and EMG by rules that have names. Delta is a frequency, high-amplitude, thalamocortical, greedy after wake, front-loaded in the night. REM is a different state with atonia and a brainstem switch that orexin stabilises. Growth-hormone mass rides N3. Cortisol should trough at midnight. Melatonin is a darkness certificate written after the SCN has spoken to the pineal via norepinephrine and AANAT. Ageing thins N3, flattens GH, flattens the melatonin peak even in the dark, and fragments continuity. Sleep restriction wrecks next-day glucose without rewriting a genome. Insomnia is a complaint with a clinic, a first-line talking therapy, and licensed hypnotics that occupy GABA-A or orexin receptors. Apnoea is an airway. A delayed phase is a clock. Those sentences are the night. They don't require a peptide. They are why a peptide that wants to sit on the night has to name which sentence it is sitting on.

In short. A night is stages, slow waves, REM, growth hormone, a cortisol dip and a melatonin rise. Insomnia is a complaint on top of that. Name which part you mean.

Let's retrace the two sequences at the size of the evidence. DSIP is WAGGDASGE, Schoenenberger and Monnier, PNAS 1977, a nonapeptide from rabbit cerebral venous blood during electrically induced delta sleep. Later architecture and HPA papers are mixed. No clean GPCR. The name describes a finding. Epithalon is AEDG, Khavinson, a tetrapeptide stand-in for pineal epithalamin. Aged-animal melatonin amplitude is a 24-hour claim. Fetal-fibroblast TRAP and length are a dish claim. Complementary peptide–DNA at TERT isn't mainstream transcription-factor biology. Anisimov's rodent lifespan tables are gerontology, not a human outcome. Independent Western replications remain thinner than both original corpora. Melatonin is a third molecule. A licensed hypnotic is a fourth. Dark rooms and a stable clock still do more everyday work than either vial. Van Cauter's restriction studies still explain more breakfast-glucose misery than either peptide. Hold those facts at once and the catalogue page becomes readable. Drop any one of them and you're back in a caption.

In short. DSIP is a 1977 nine-mer with mixed later tests and no named receptor. Epithalon is a four-mer with melatonin and telomerase papers. Neither is a night in a bottle.

What a sceptical reader should leave with is a topology, not a shopping list. Sleep architecture is a scored table. Delta waves are a frequency. The pineal is an AANAT factory downstream of the SCN. DSIP is provenance plus a mixed bioassay file. Epithalon is two clocks — melatonin amplitude and TERT — with an open mechanism and a starting library. Neighbourhood isn't identity. A reading list can sit them together because searchers type one complaint. An experiment can't sit them together as one occupancy, and this journal won't. The 10 mg DSIP cake is the named nonapeptide for architecture and HPA assays. The 50 mg Epithalon cake is the named tetrapeptide for melatonin-curve and TRAP assays. CBT-I, CPAP, timed light, and the formulary hypnotics remain where they were. If your experiment needs the nine-mer, weigh it, score the night, and write the route. If it needs the four-mer, control the photoperiod and name the oscillator. If it needs a medicine, this catalogue doesn't sell one.

In short. Leave with the map: scored stages, a pineal factory, a nine-mer from an isolation, a four-mer on two ageing clocks. The vials are for the assays that map requires.

The public papers are short enough to actually read. Schoenenberger and Monnier, PNAS 1977, the isolation. Rechtschaffen and Kales, 1968, and the AASM 2007 revision, the scoring. Borbély's two-process model, Process S and Process C. Steriade on thalamocortical delta. Spiegel, Leproult, Van Cauter, Lancet 1999, sleep debt and the glucose curve. Klein on AANAT. Takahashi on the clock loop. Hayflick 1961, Greider and Blackburn 1985, de Lange on shelterin, Khavinson and Bondarev 2003–2004 on TRAP in fibroblasts. That's a fortnight of evenings, not a guru. The insomnia headlines will still be there when you come back, and they will look smaller. Ageing, on this node, is a thinned N3, a flatter GH pulse, a flatter melatonin peak, a noisier SCN, and a telomere debit the soma accepted as tumour suppression. That sentence is a research programme. It isn't a diagnosis, and it isn't a product. The programme runs on HPLC-characterised reagents, on nights whose photoperiod you state, on hypnograms rather than well-being scores, and on a willingness to publish the trial that didn't move the endpoint.

In short. A short stack of named papers covers the isolation, the scoring rules, the clock, the night enzyme, the glucose cost of lost sleep, and the telomerase dish work. Read those first.

Research-use-only. Not for human consumption / not a medicine. The lyophilised DSIP on this listing is WAGGDASGE, HPLC-characterised, labelled for in-vitro and laboratory animal work: a hypnogram, a spectral band, an HPA curve, a receptor hunt that still hasn't closed. The lyophilised Epithalon is AEDG for a dark-cycle melatonin curve, a TRAP gel, a telomere length, a karyotype. The physiology in the paragraphs above is public, cited, and older than either vial. Use it to design the experiment you have the controls for, with the stage named, the oscillator named, and the photoperiod written down. Read Schoenenberger, read Van Cauter, read Khavinson as a starting library, then weigh the cake. We'll sell you the sequences. We won't tell you either of them is a night's rest you can deposit in a vein and draw as sleep. Architecture is a set of scored rates. Those rates you can measure, in a laboratory, with a tracing on the bench beside the chromatogram.

In short. The vials are research chemicals for named sleep-architecture and pineal assays, not medicines and not a night's rest. The biology is public. Measure the rate you actually claim.